Q4 FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 5, 2026
aTYR PHARMA INC (ATYR) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$9.4 million. As of Jun 30, 2026 it held $57.4 million in cash and investments and $11.3 million in total debt.
Revenue
$0
Net income
$-10.31M
+47.2% vs year-ago quarter
Operating cash flow
$-9.35M
+32.7% vs year-ago quarter
Free cash flow
$-9.42M
+32.2% vs year-ago quarter
EPS
$-0.11
+50.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
98.09M
+0.1% vs year-ago quarter
Net cash
$46.12M
Q2 FY2026
Operating margin
-14076.3%
Q3 FY2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ATYR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1339970
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $190,000 | $0 |
| Operating income | -$10.9M | -$11.4M | -$14.8M | -$26.7M | -$20.3M |
| Net income | -$10.3M | -$10.8M | -$14.0M | -$25.7M | -$19.5M |
| Diluted EPS | -$0.11 | -$0.11 | -$0.14 | -$0.26 | -$0.22 |
| Operating cash flow | -$9.4M | -$12.5M | -$12.2M | -$20.5M | -$13.9M |
| Free cash flow | -$9.4M | -$12.7M | -$12.2M | -$20.5M | -$13.9M |
| Total assets | $69.8M | $79.7M | $93.0M | $106.7M | $101.5M |
| Stockholders' equity | $48.8M | $57.9M | $67.5M | $80.2M | $74.8M |
| Cash and investments | $57.4M | $66.5M | $78.7M | $90.2M | $80.3M |
| Total debt | $11.3M | $11.7M | $12.0M | $12.4M | $12.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 6, 2026 | Nov 6, 2026 |
| 10-Q | Quarterly report | Nov 6, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 27, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 16, 2026 | Oct 16, 2026 |
| 8-K |
Current report
Other events
|
Sep 24, 2026 | Sep 24, 2026 |
All 755 aTYR PHARMA INC SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.